CVE:ACST Acasti Pharma (ACST) Stock Price, News & Analysis → The Gold Grab of the Century (From Colonial Metals) (Ad) Free ACST Stock Alerts C$0.58 +0.01 (+1.75%) (As of 03/27/2023) Add Compare Share Share Today's RangeC$0.56▼C$0.5850-Day RangeC$0.58▼C$0.5852-Week RangeC$0.47▼C$1.66Volume2,450 shsAverage Volume6,576 shsMarket CapitalizationC$25.87 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Acasti Pharma alerts: Email Address Ad Porter & CompanyElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. About Acasti Pharma Stock (CVE:ACST)Acasti Pharma Inc., a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for cardiovascular diseases. It is evaluating strategic partnerships for the clinical development of CaPre. The company was incorporated in 2002 and is headquartered in Laval, Canada.Read More ACST Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ACST Stock News HeadlinesApril 6, 2024 | finance.yahoo.comAcasti Pharma Inc. (ACST)March 14, 2024 | edition.cnn.comAcasti Pharma Inc. Class AMay 5, 2024 | Stansberry Research (Ad)Gold ManiaFormer Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).February 25, 2024 | msn.comAcasti Pharma (ACST) Price Target Increased by 200.00% to 6.12February 12, 2024 | finance.yahoo.comAcasti Announces Third Fiscal Quarter 2024 Financial Results and Business HighlightsDecember 25, 2023 | finance.yahoo.comWill Acasti Pharma (NASDAQ:ACST) Spend Its Cash Wisely?November 14, 2023 | investing.comAcasti Pharma (ACST) Earnings Dates & ReportsNovember 11, 2023 | morningstar.comAcasti Pharma Inc Class A ACSTMay 5, 2024 | Stansberry Research (Ad)Gold ManiaFormer Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).September 26, 2023 | benzinga.comWhy Acasti Pharma (ACST) Stock Is Exploding HigherSeptember 6, 2023 | technews.tmcnet.comAcasti to Participate in the H.C. Wainwright Global Investment ConferenceAugust 11, 2023 | finanznachrichten.deAcasti Pharma, Inc.: Acasti Announces First Quarter 2024 Financial Results and Business HighlightsJune 23, 2023 | finanznachrichten.deAcasti Pharma Inc.: Acasti Pharma Reports Fiscal Year 2023 Operational ResultsJune 23, 2023 | finance.yahoo.comAcasti Pharma Reports Fiscal Year 2023 Operational ResultsJune 22, 2023 | finance.yahoo.comAcasti Announces Appointment of New Scientific Advisory Board MembersJune 20, 2023 | sg.finance.yahoo.comACST - Acasti Pharma Inc.April 7, 2023 | theglobeandmail.comClosing Bell: Acasti Pharma Inc up on Monday (ACST)April 4, 2023 | seekingalpha.comAcasti Pharma announces CEO transitionMarch 16, 2023 | morningstar.comAcasti Pharma Inc. Centralizes Marketplace for Shares on the Nasdaq with Voluntary Delisting from TSX Venture Exchange | MorningstarMarch 8, 2023 | finance.yahoo.comAcasti Pharma to Participate in Oppenheimer 33rd Annual Healthcare ConferenceMarch 4, 2023 | finance.yahoo.comWe're Hopeful That Acasti Pharma (CVE:ACST) Will Use Its Cash WiselyMarch 1, 2023 | finance.yahoo.comAcasti Pharma Recognizes Rare Disease DayFebruary 28, 2023 | msn.comHas Acasti Pharma (ACST) Outpaced Other Medical Stocks This Year?January 13, 2023 | benzinga.comAcasti Pharma to Present at Sidoti Virtual Investor Conference on January 18November 15, 2022 | seekingalpha.comAcasti Pharma Inc. (ACST) Q2 2023 Earnings Call TranscriptNovember 9, 2022 | it.tmcnet.comAcasti Pharma to Present at Q4 Investor SummitNovember 8, 2022 | tmcnet.comAcasti Pharma to Report Second Quarter 2023 FinancialSee More Headlines Receive ACST Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acasti Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeCVE SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolCVE:ACST Previous SymbolCVE:APO CUSIPN/A CIKN/A Webwww.acastipharma.com Phone+1-450-6864555FaxN/AEmployees32Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)C($0.54) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeC$-17,250,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-16.60% Return on Assets-8.25% Debt Debt-to-Equity Ratio0.52 Current Ratio9.74 Quick Ratio9.41 Sales & Book Value Annual SalesC$115,000.00 Price / Sales224.99 Cash FlowC$0.93 per share Price / Cash Flow0.63 Book ValueC$2.17 per share Price / Book0.27Miscellaneous Outstanding Shares44,610,000Free FloatN/AMarket CapC$25.87 million OptionableNot Optionable Beta1.22 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMs. Janelle D'Alvise (Age 68)Pres, CEO, Corp. Sec. & Director Comp: $620.16kDr. Pierre Lemieux M.D. (Age 58)Ph.D., Co-Founder, COO & Chief Scientific Officer Comp: $398.75kMr. Brian D. Ford CPA (Age 64)CA, Chief Financial Officer Comp: $340.84kDr. George Kottayil (Age 60)Chief Operating Officer of US Comp: $160.16kMr. Prashant KohliChief Commercial OfficerDr. Yves Lachance Ph.D.VP of Quality & ComplianceMs. Christine PelletierSr. Director of HRMore ExecutivesKey CompetitorsAptose BiosciencesTSE:APSLiberty BiopharmaCVE:LTYCovalon TechnologiesCVE:COVCeaproCVE:CZOReunion NeuroscienceTSE:REUNView All Competitors ACST Stock Analysis - Frequently Asked Questions How have ACST shares performed in 2024? Acasti Pharma's stock was trading at C$0.58 at the beginning of 2024. Since then, ACST stock has increased by 0.0% and is now trading at C$0.58. View the best growth stocks for 2024 here. What other stocks do shareholders of Acasti Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Acasti Pharma investors own include Matinas BioPharma (MTNB), Aurora Cannabis (ACB), SCYNEXIS (SCYX), Block (SQ), Nokia Oyj (NOK), Axsome Therapeutics (AXSM), Blink Charging (BLNK), Inovio Pharmaceuticals (INO), Okta (OKTA) and Tesla (TSLA). How do I buy shares of Acasti Pharma? Shares of ACST stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. This page (CVE:ACST) was last updated on 5/5/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldElon to Transform U.S. Economy? Porter & CompanyThe asset beating inflation by 4xColonial MetalsCould Your Accounts Be Frozen?Allegiance GoldGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlaceUrgent Nvidia WarningAltimetryDid You Get Your Free Bitcoin Yet?Crypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acasti Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.